Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy of T-817MA in AD patients to
treat dementia. Efficacy will be cognitive function, as measured by the ADAS-cog cognitive
assessment.
The secondary objectives of the study are to evaluate the safety of T-817MA and the
activities of daily living (assessed with the ADCS-ADL) of AD patients taking T-817MA, and to
evaluate the efficacy of T-817MA in AD patients with an overall global assessment using the
ADCS-CGIC.
Phase:
Phase 2
Details
Lead Sponsor:
FUJIFILM Toyama Chemical Co., Ltd. Toyama Chemical Co., Ltd.